# A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users

> **NCT02144415** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 80 (actual)

## Conditions studied

- Healthy Volunteers
- Drug Users

## Interventions

- **DRUG:** EB-1020 400 mg
- **DRUG:** EB-1020 800 mg
- **DRUG:** lisdexamfetamine 150 mg
- **DRUG:** d-amphetamine 40 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02144415
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-01
- **Primary completion:** 2014-07-01
- **Final completion:** 2014-07-01
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02144415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02144415, "A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02144415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*